Gilead Sciences stock nears its all-time high
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer c ...
Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences. | ...
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...